L ung cancer remains the deadliest cancer worldwide despite improvements in diagnostic and therapeutic techniques. 1 Its incidence has yet to peak in many parts of world, particularly in China. The prognosis for lung cancer patients is generally poor, with an overall 5-year survival rate of approximately 15%, and it has shown little improvement in recent decades. 2, 3 Several independent prognostic factors for survival have been identified: performance status, disease stage, age, sex, and amount of weight lost. 4 Some of these factors are useful when choosing treatment options for an individual, principally disease stage and performance status. However, the discriminant value of most potential prognostic biologic markers is insufficient to predict the optimal therapeutic course for an individual. For non-small cell lung cancers (NSCLC) in earlier disease stages, surgery is a potentially curative measure; for more advanced stages, chemotherapy and radiotherapy are standard treatments. Nevertheless, the benefit of combination chemotherapy is limited, and no significant benefit is associated with inadequate chemotherapy. Thus, it is important to identify biologic markers with predictive value for the survival of patients undergoing treatment.
Angiogenesis, the formation of new tumor-feeding blood vessels from preexisting vasculature, is critical for the development and subsequent growth of human tumors and is a prerequisite for metastasis. Proangiogenic factors secreted by tumor cells and/or host factors stimulate endothelial cells to proliferate and to form new blood vessels that are qualitatively poor and often leaky. As few as 60 to 200 tumor cells can initiate angiogenesis. Although basic fibroblast growth factor and platelet-derived growth factor are involved in angiogenesis, proteins in the vascular endothelial growth factor (VEGF) family are the predominant proangiogenic factors. The VEGF family of growth factors is comprised of several structurally related molecules, including VEGFA, VEGFB, VEGFC, and VEGFD. 5, 6 The major mediators of tumor angiogenesis are VEGFA, usually referred to as VEGF, and vascular endothelial growth factor receptor 2 (VEGFR2 or KDR/Flk-1). The binding of VEGF to VEGFR2 activates multiple signaling pathways, 7 resulting in the upregulation of genes that promote the proliferation and migration of endothelial cells as well as their survival and vascular permeability. Interestingly, the binding of VEGFC to VEGFR3 mediates lymphangiogenesis.
In addition, specifically targeted molecular therapy has been anticipated as an effective addition to combination chemotherapy. Recently, bevacizumab (a humanized monoclonal antibody directed against VEGF) was shown to increase overall survival of patients with advanced NSCLC in combination with standard chemotherapy in a randomized phase 3 trial. 8 The association between VEGF overexpression and survival in patients with lung cancer has been studied for over a decade. However, no consensus has been reached; conflicting results have been reported from different laboratories. We therefore carried out a meta-analysis of data from published studies to quantitatively review the effect of VEGF overexpression in tumor tissue and/or blood serum on survival in patients with lung cancer.
MATERIALS AND METHODS

Search Strategy and Study Selection
The electronic databases PubMed, Embase, Web of Science, and CNKI (China National Knowledge Infrastructure) were searched for studies to include in the present meta-analysis. An upper date limit of March 31, 2008 was applied; we used no lower date limit. Searches included the terms "lung cancer," "VEGF," "vascular endothelial growth factor," and "prognosis." We also reviewed the Cochrane Library for relevant articles. The references reported in the identified studies were also used to complete the search.
Studies eligible for inclusion in this meta-analysis met the following criteria: (1) measure VEGF expression in the primary lung cancer tissue with immunohistochemistry (IHC) or enzyme linked immunosorbent assay (ELISA)/reverse transcription-polymerase chain reaction (RT-PCR); (2) provide information on survival (studies investigating response rates only were excluded); (3) have a follow-up time exceeding 5 years (3 years for SCLC); and (4)when the same author reported results obtained from the same patient population in more than one publication, only the most recent report, or the most complete one, was included in the analysis. Two reviewers (P.Z. and J.W.) independently determined study eligibility. Disagreements were resolved by consensus.
Data Extraction and Quality Assessment
The final articles included were assessed independently by two reviewers (P.Z. and J.W.). Data retrieved from the reports included author, publication year, patient source, histology, disease stage, test method, cutoff value, VEGF positive, and survival data ( Table 1 ). If data from any of the above categories were not reported in the primary study, items were treated as "not applicable." We did not contact the author of the primary study to request the information.
To assess trial methodology, publications were read independently by two investigators (PZ and XQL) and given a quality score according to Steele's method, 9 which designed the methodological scale of biologic prognostic factors for lung cancer on behalf of European Lung Cancer Working Party. The overall score evaluated several dimensions of the methodology, grouped into four main categories: scientific design; description of the methods used to identify abnormal VEGF expression; how well the results could be generalized; and the analysis of the study data. A maximum of 10 points could be given for each category; hence, the overall maximum score was 40 points. When an item was not applicable in a study, the theoretically attributable points were not taken into account. Final scores were expressed as percentages ranging from 0 to 100%, with higher values indicating better methodology.
Statistical Methods
The correlation between two continuous variables was measured by the Spearman rank correlation coefficient. Nonparametric tests were used to compare the distribution of quality scores according to the value of a discrete variable.
For the quantitative aggregation of the survival results, hazard ratios (HR) and their 95% confidence intervals (CIs) were combined to give the effective value. When these statistical variables were not given explicitly in an article, they were calculated from available numerical data using methods reported by Parmar et al. 10 Heterogeneity of the individual HRs was calculated with 2 tests according to Peto's method. 11 Meanwhile, heterogeneity test with I 2 statistic and Q statistic was performed. All the studies included were categorized by histology, disease stage, patient race, VEGF isoform, and laboratory techniques used. Individual meta-analysis was conducted in each subgroup. If HRs were found to have fine homogeneity, a fixed effect model was used for secondary analysis; if not, a random-effect model was used. In this meta-analysis, DerSimonian-Laird random effects analysis 12 was used to estimate the effect of VEGF overexpression on survival. By convention, an observed HR Ͼ1 implies worse survival for the group with VEGF overexpression. The impact of VEGF on survival was considered to be statistically significant if the 95% CI did not overlap with 1. Horizontal lines represent 95% CIs. Each box represents the HR point estimate, and its area is proportional to the weight of the study. The diamond (and broken line) represents the overall summary estimate, with CI represented by its width. The unbroken vertical line is set at the null value (HR ϭ 1.0).
Evidence of publication bias was sought using the methods of Egger et al. 13 and Begg et al. 14 Moreover, contour-enhanced funnel plot 15 was performed to aid in interpreting the funnel plot. If studies appear to be missing in areas of low statistical significance, then it is possible that the asymmetry is due to publication bias. If studies seem to be missing in areas of high statistical significance, then publication bias is a less likely cause of the funnel asymmetry. 
RESULTS
Study Selection and Characteristics
Three hundred and six potentially relevant citations were reviewed, and 51 studies met the criteria set forth in the search strategy and study selection section (Figure 1 ). Fiftyone studies 16 -66 published between 1997 and 2008 were eligible for this systematic review with meta-analysis. All reported the prognostic value of VEGF status for survival in patients with lung cancer. The total number of patients included was 5386, ranging from 34 to 335 patients per study (median, 91). Two publications 67, 68 were excluded as they were redundant with other included studies. The major characteristics of the 51 eligible publications are reported in Table 1 .
These publications followed several different patient cohorts. Forty-six studies dealt with all types of NSCLC, whereas five dealt with SCLC. The NSCLC studies considered either all lung cancer subtypes (n ϭ 46), adenocarcinomas (n ϭ 5), or squamous cell carcinomas (n ϭ 2). Forty-five studies had information for stages I-III, seven for stage I disease, and only one for all stages I-IV. In all patients with NSCLC, surgery was performed as the foremost treatment measure.
Thirty-five studies used IHC to evaluate VEGF expression in NSCLC, six studies used RT-PCR to assess VEGF mRNA overexpression in NSCLC, and four studies used ELISA to determine VEGF expression. VEGFC and VEGFR3/flt-1 were detected in eight and four studies, respectively.
Among the 44 studies evaluating VEGF expression in NSCLC, 30 studies (3458 patients: 71.2%) were performed in Asian populations, and the remaining 14 studies (1368 patients: 28.8%) followed European or American patients. Twenty-eight of the 51 studies identified VEGF overexpression as an indicator of poor prognosis, and the other 23 studies showed no statistically significant impact of VEGF overexpression on survival. The proportion of patients exhibiting VEGF overexpression in individual studies ranged from 22 to 81% by IHC, from 15 to 79% by RT-PCR, and from 31 to 53% by ELISA.
Quality Assessment
Overall, the global quality score of the included studies ranged from 42.5 to 65.0% with a mean of 52.5% ( Table 2) . Concerning the global score, there was no statistically significant difference between the 32 positive and the 19 negative trials (mean of 53.8% versus 50.3%, p ϭ 0.624).
There was no statistical difference in global score between studies that assessed VEGF status with IHC (n ϭ 39) or with molecular biology (RT-PCR or ELISA) (n ϭ 12), with scores of 45.5% and 47.3%, respectively (p ϭ 0.896). However, there was a significant difference for the description of the laboratory methodology, with molecular biology better described than IHC (5.2 of 10 compared with 4.6 of 10, p ϭ 0.025).
Meta-Analysis
The results of the meta-analysis are reported in Table 3 and in Figure 2 . Overall, the combined HR for all 44 eligible The data extracted were adequate to aggregate the studies of stage I NSCLC, adenocarcinoma, and SCLC for subgroup analyses. We found one significant correlation, between VEGF expression and stage I NSCLC. When we aggregated seven studies that reported results for stage I NSCLC, the combined HR was statistically significant: HR 1.57 (95% CI: 1.43-1.70, Q ϭ 16.7, I 2 ϭ 64.2%, p ϭ 0.01 for heterogeneity) ( Figure 2D ). We also observed a statistically significant effect of VEGF expression on survival in patients with adenocarcinoma with an HR of 1.27 (95% CI: 1.06 -1.47, Q ϭ 20.5, I 2 ϭ 80.5%, p ϭ 0.00 for heterogeneity) ( Figure 2B ) and in patients with SCLC with an HR of 1.41 (95% CI: 1.17-1.65, Q ϭ 9.8, I 2 ϭ 59.1%, p ϭ 0.04 for heterogeneity) ( Figure 2C ). There were not adequate data to aggregate studies of stage II or III NSCLC.
However, no statistically significant effect on survival was observed for VEGF subtype. When we limited the analysis to the eight studies that investigated VEGFC expression in patients with NSCLC, the combined HR was 1.22 (95% CI: 0.96 -1.47, Q ϭ 6.36, I 2 ϭ 0, p ϭ 0.499 for heterogeneity) (Figure 2E ). When the four studies investigating VEGFR3/flt-1 expression in patients with NSCLC were analyzed, the combined HR was 1.58 (95% CI: 0.96 -2.20, Q ϭ 5.2, I 2 ϭ 42.6%, p ϭ 0.156 for heterogeneity) ( Figure 2F ).
Publication Bias
Begg's funnel plot and Egger's test were performed to assess the publication bias in the literature. All 44 eligible studies investigating patients with NSCLC yielded a Begg's test score of p ϭ 0.058 and an Egger's test score of p ϭ 0.096, meanwhile according to the contour-enhanced funnel plot of 44 studies (Figure 3) , the absence of publication bias was found in all 44 studies. Similar results were found for the five SCLC studies (p ϭ 0.462 and 0.781); 5 studies of patients with adenocarcinoma (p ϭ 0.462 and 0.737); 7 studies including patients with stage I NSCLC (p ϭ 0.23 and 0.659); 8 studies investigating EVGFC expression in patients with NSCLC (p ϭ 1.00 and 0.99) (data not shown); and 4 studies investigating VEGFR3/flt-1 expression in patients Score distributions are summarized by the median values; Negative, no significant prognostic factor for survival; poor, as significant positive prognostic factor for survival; IHC, immunohistochemistry; MB, molecular biology (reverse transcription-polymerase chain reaction and enzyme linked immunosorbent assay). a Score out of 10. with NSCLC (p ϭ 0.308 and 0.157). These results suggest that there is no publication bias at work.
DISCUSSION
Since the publication of Folkman's innovative tumor angiogenesis hypothesis in 1971, 69 there has been great interest in understanding the role of VEGF in this process. Reports of the prognostic value of VEGF expression in NSCLC patients date back to the 1990s. However, the first VEGF-targeting drug (bevacizumab) developed as an inhibitor of angiogenesis was not approved by the US Food and Drug Administration until 2004. 70 A true understanding of the mechanism of action of anti-VEGF therapies requires more accurate evaluation of the impact of VEGF expression on patient survival.
In this systematic review with meta-analysis, we have combined 51 published studies including 5386 patients with lung cancer to yield summary statistics that indicate that VEGF overexpression has a significant correlation with poor survival in patients with NSCLC and SCLC. This correlation was observed in both Asian and non-Asian study populations. When analysis was restricted to stage I NSCLC, we found that the combined HR (1.57) was larger than the combined HR for all 44 eligible studies of stages I-III NSCLC (1.46), FIGURE 2. Meta-analysis (Forest plot) of the 44 evaluable studies assessing vascular endothelial growth factor (VEGF) in nonsmall cell lung cancer (NSCLC) (A); the five evaluable studies assessing VEGF in adenocarcinoma (B); the five evaluable studies assessing VEGF in small cell lung cancer (SCLC) (C); the seven evaluable studies assessing VEGF in stage I NSCLC (D); the eight evaluable studies assessing VEGFC in NSCLC (E); the four evaluable studies assessing vascular endothelial growth factor receptor 3/Flt-1 in NSCLC (F).
suggesting that VEGF expression could be an important prognostic factor for early-stage NSCLC. When we limited our analysis to adenocarcinoma, we found a worse prognostic significance of VEGF. Data were not sufficient to determine the prognostic value of VEGF expression in squamous cell carcinoma. The method used to detect VEGF did not have an impact on significance; results were similar for studies that used IHC or RT-PCR.
Subgroup analyses revealed that neither VEGFC overexpression nor VEGFR3/flt-1 had a significant impact on survival of NSCLC patients. VEGFC was a specific inducer of mediated lymphangiogenesis. 71 VEGFC expression levels are increased in many malignant tissues, including lung cancers. However, the value of VEGFC expression as a prognostic tool for NSCLC has been controversial. Unfortunately, our meta-analysis further supports the hypothesis that VEGFC overexpression is not associated with survival in NSCLC patients.
The present systematic review with meta-analysis suggests that VEGF overexpression is an indicator of poor prognosis for patients with SCLC. Thus, inhibiting VEGFmediated angiogenesis might be an effective treatment for SCLC, in combination with chemotherapy. Recently, several phase 2 trials 72,73 have shown some clinical benefits for the VEGF-targeting monoclonal antibody bevacizumab in patients with untreated extensive disease-SCLC. Meanwhile, phase 3 trials of bevacizumab as a first-line therapy in patients with extensive disease-SCLC are planned for the near future. 74 Recently, several systematic reviews 9,75-82 with metaanalyses on other biologic prognostic factors for NSCLC had been reported. P53, microvessel density, HER-2, Ki-67, and RAS might be poor prognostic factors for survival in NSCLC, however, Bcl-2 might be better prognostic factor for survival in NSCLC. The prognostic significance of EGFR and Survivin had been under controversy. Moreover, several studies [83] [84] [85] had reported that the expression of VEGF, Gult-1 (glucose transporter 1), and microvessel density were all significantly correlated with 18F-FDG (2-18F-fluoro-2-deoxy-D-glucose) uptake of positron emission tomographycomputed tomography, these three biomarkers showed a positive correlation with the 18F-FDG uptake.
Our data were consistent with the results of a previous meta-analysis 86 published in French that showed an association between VEGF overexpression and poor survival of patients with NSCLC. This analysis included only 15 studies, and the data were insufficient to determine the prognostic value of VEGF in SCLC. In addition, that meta-analysis did not determine the combined HR for subgroups divided according to histology, disease stage, and subtype of VEGF or method of VEGF detection. We have improved upon that previous meta-analysis by including more recent related studies and by generally using a more comprehensive search strategy. Screening, study selection, and quality assessment were performed independently and reproducibly by two reviewers. We also explored heterogeneity and potential publication bias in accordance with published guidelines.
This systematic review with meta-analysis was complicated by heterogeneity issues. We found highly significant heterogeneity among 44 studies of NSCLC and five studies of SCLC. When the analysis was limited to 14 non-Asian studies of NSCLC and 8 studies of VEGFC expression in NSCLC, heterogeneity was not detected, but heterogeneity was detected when analyses were limited to the five studies including only adenocarcinomas or seven studies including only stage I NSCLC. Therefore, histologic type and disease stage were not a major source of heterogeneity. The heterogeneity in this study could be explained by the patient type or by differences in the method used to detect VEGF status. Thirty-five of the studies included in our analysis used IHC to detect VEGF, four used ELISA, and six used RT-PCR. When analyzed separately, heterogeneity was still found in the 35 studies that used IHC; however, no heterogeneity was found among the six studies that used RT-PCR.
Diversity within the techniques used to identify alteration of the VEGF status is another potential source of bias. The technique used for IHC varies considerably among the 35 studies in our analysis. The primary antibodies used were not identical, and many different cutoffs for VEGF positive tissues (10 -50%, different scores) were used. To exclude technique bias, subgroup analyses were performed for the most frequently used methods: IHC, ELISA, and RT-PCR. The results were consistent within all methods, with poorer survival in cases where VEGF was overexpressed, suggesting that the techniques are unlikely to be a source of bias. However, it is still important to use well defined, standardized methods to reproducibly evaluate biologic markers.
Another potential source of bias is related to the method of HR and 95% CI extrapolation. If these statistics were not reported by the authors, we calculated them from the data available in the article. If this was not possible, we extrapolated them from the survival curves, necessarily making assumptions about the censoring process. Data for multivariate survival analysis reported in the article were included in the present systematic review with meta-analysis; if these data were not available, data calculated from survival curves by univariate analysis were included. These results should be confirmed by an adequately designed prospective study. Furthermore, the exact value of VEGF overexpression status needs to be determined by appropriate multivariate analysis. Unfortunately, few prospectively designed prognostic studies concerning biomarkers have been reported; thus, our collection of many retrospective studies revealed more significance.
Additional biases could be introduced by the methodology used to perform our systematic review with metaanalysis. We performed a methodological assessment of the studies to avoid selection biases where possible. The absence of a detectable difference in quality score between significant and nonsignificant studies, and between evaluable and nonevaluable studies, encouraged us to perform a meta-analysis of the results from the individual trials.
Publication bias 87 is a major concern for all forms of meta-analysis; positive results tend to be accepted by journals, while negative results are often rejected or not even submitted. The present analysis does not support publication bias; the obtained summary statistics likely approximate the actual average. However, it should be noted that our metaanalysis could not completely exclude biases. For example, the study was restricted to articles published in English and Chinese, which probably introduced bias.
In conclusion, VEGF overexpression was associated with a poor prognosis in patients with lung cancer in the present systematic review with meta-analysis. Interestingly, our meta-analysis suggests that VEGF has a detrimental effect on survival in stage I NSCLC. Use of VEGF as a prognostic tool at the earliest stage of NSCLC could be of clinical interest to allow the selection of patients eligible for induction or adjuvant chemotherapy. However, VEGFC and VEGFR3/flt-1 overexpression seems to have no significant impact on survival of NSCLC patients, as determined in our meta-analysis. These results should be confirmed by an adequately designed prospective study.
